Hyperbaric oxygen can induce angiogenesis and recover erectile function

Hadanny et al. (2018, International Journal of Impotence Research) is the first published trial to demonstrate mechanism-level vascular repair from HBOT in vasculogenic erectile dysfunction — meaning HBOT was shown not just to improve symptoms, but to drive structural change (new blood vessel formation) in penile tissue. What the trial measured. Two primary clinical outcomes: the International Index of Erectile Function (IIEF) questionnaire and a Global Efficacy Question (GEQ). The objective backbone was perfusion MRI of the corpus cavernosum, measured before and after the protocol — designed to detect angiogenic structural change directly rather than infer it from symptom improvement. Who was studied. Thirty men with documented chronic vasculogenic erectile dysfunction (mean age 59.2 ± 1.4 years; mean ED duration 4.2 ± 0.6 years), with reduced penile blood flow confirmed at baseline. The vasculogenic subtype is critical: ED has multiple etiologies (psychogenic, neurogenic, hormonal, vasculogenic), and HBOT mechanism most directly applies to the vascular subtype. Protocol parameters. Forty daily HBOT sessions at 2.0 ATA, 100% oxygen, 90 minutes per session, 5 days per week — totaling approximately 8 weeks. The protocol mirrors the Israeli group's other 40-session trials (Efrati 2013 stroke, Boussi-Gross 2013 TBI), allowing cross-trial mechanism comparison. Results (verbatim from abstract). HBOT significantly improved all IIEF domains by 15–88% (p < 0.01). The erectile function domain itself improved by 88% (p < 0.0001) — a large effect by any clinical standard. 80% of patients reported a positive outcome on the GEQ. Most importantly, perfusion MRI showed a 153.3% ± 43.2% increase in K-trans values in the corpus cavernosum (p < 0.0001) — direct imaging evidence of angiogenesis (new blood vessel formation). This is the structural-change finding that distinguishes the trial from the broader pharmacological ED literature. Limitations. Sample size (n=30) is small. The trial did not have a sham-control arm, limiting blinding. The cohort was specifically vasculogenic ED — the result does not directly extend to ED of other etiologies. Long-term durability was reported at follow-up but the cohort is too small to establish durability with confidence at scale. What it means in practice. The clinical implication is meaningful: HBOT may treat the vascular root cause of ED rather than just the symptom — distinguishing it from PDE5 inhibitors (sildenafil, tadalafil) which produce on-demand vasodilation without repairing the underlying tissue. For men whose ED is part of broader cardiovascular concerns, this represents a fundamentally different therapeutic approach. The 2.0 ATA protocol requires a clinical chamber; 1.5 ATA home chambers cannot replicate it. How it relates to other indexed trials. Hadanny ED 2018 is mechanistically connected to the broader angiogenesis story across the Saturate site — the same biology underlies Hachmo 2021 (dermal angiogenesis +153% K-trans here vs. +significant blood vessel count in skin), Zhang 2022 (wound healing via angiogenesis), and Bennett 2016 (radiation tissue repair). The vascular thread runs through multiple Saturate condition pages. Source: PubMed PMID 29773856.